Results 191 to 200 of about 212,907 (281)

Maximizing treatment response in patients with neuropathic-subtype postural orthostatic tachycardia syndrome. [PDF]

Front Neurol
Rilinger RG, Chin AY, Cantrell C, Levine M, Stallkamp Tidd SJ, Wilson R.   +5 more
europepmc   +1 more source

Cholesterol‐Mediated Metabolic‐mechanotransductive Crosstalk Orchestrates Castration Resistance in Prostate Cancer

Advanced Science, EarlyView.
Full androgen deprivation (FAD) induces paracrine cholesterol in prostate cancer that drives the polarization of cancer‐associated fibroblasts (CAFs) and subsequent elevated matrix stiffness. Matrix stiffness in turn potentiates tumor cell survival under FAD pressure via dual mechanotransductive activation of the IRE1α‐XBP1s stress‐response axis ...
Shaojie Liu, Chao Xu, Jun Jiang, Limin He, Yike Zhou, Zhengxuan Li, Yu Li, Keying Zhang, Fa Yang, Tong Lu, Hongtao Song, Hai Zhu, Zhihao Hu, Xiaolong Zhao, Kai Gan, Hongji Li, Bo Yang, Rui Zhang, Weihong Wen, Donghui Han, Weijun Qin   +20 more
wiley   +1 more source

Prognostic Preoperative Factors in Surgical Patients with Colorectal Liver Metastases: A Nationwide Multicenter Study. [PDF]

J Gastrointest Cancer
Knøfler LA, Klubien J, Larsen PN, Hillingsø JG, Kirkegaard J, Pless T, Stender MT, Lousdal ML, Nielsen SD, Pommergaard HC.   +9 more
europepmc   +1 more source

RNF138‐Mediated Ubiquitination and Degradation of NS5 Restricts Tick‐Borne Encephalitis Virus Infection

Advanced Science, EarlyView.
Host‐specific compatibility between RNF138‐like proteins and flavivirus NS5 determines NS5 stability. Mammalian RNF138 but not arthropod homologs recognizes and induces conserved NS5/RdRp K48‐linked ubiquitination and proteasomal degradation, thereby restricting viral replication. Ectopic RNF138 in mice attenuates TBEV‐induced pathogenesis. (Created in
Jialiang Sun, Weijing Yang, Hao Zhou, Shuai Li, Xin Jiang, Jianyang Gu, Wenyan Zhang   +6 more
wiley   +1 more source

Benchmarking progression-free survival ratio as primary endpoint in precision oncology clinical trials. [PDF]

NPJ Precis Oncol
Nichetti F, Hüllein J, du Rusquec P, Pleasance E, Chen L, Mock A, Horak P, Ambrosini P, Rota S, Niger M, Agnelli L, Tinè G, Edelmann D, Le Tourneau C, Laskin J, Pruneri G, Wang C, Hübschmann D, de Braud F, Fröhling S, Mariani L.   +20 more
europepmc   +1 more source

CCL3 and IL‐7 Synergistically Enhance CAR‐T Efficacy in Solid Tumors

Advanced Science, EarlyView.
Synergistic delivery of CCL3 and IL‐7 by CAR‐T cells overcomes the immunosuppressive tumor microenvironment by enhancing cell infiltration, survival, and local immune reprogramming. This also establishes positive feedback that amplifies anti‐tumor activity and memory responses in both CAR‐T and endogenous T cells, presenting a robust therapeutic ...
Huanpeng Chen, Xiaoyun Luo, Huixin Gao, Yujing Ke, Yu Zhan, Xiaoting Xu, Xiaoxiao Xiong, Fengjiao Wei, Si Yang, Zhonghua Liu, Bolan Yu, Zhaofeng Huang, Yingjie Bian   +12 more
wiley   +1 more source

Evaluation of the Naples Prognostic Score in Patients with Head and Neck Squamous Cell Carcinoma. [PDF]

Nutrients
Wissa M, Lein A, Jank BJ, Heiduschka G, Kadletz-Wanke L, Brkic FF.   +5 more
europepmc   +1 more source

Tumor‐Specific Delivery of CD28 siRNA via Lyso‐PC C‐16 Modified Lipid Nanoparticles Overcomes Anti‐PD‐1 Resistance by Remodeling Tumor Microenvironment

Advanced Science, EarlyView.
This study develops 16:0 LPC‐modified lipid nanoparticles (LPC‐LNPs) with cancer cell specificity by exploiting altered tumor lipid metabolism. LPC‐LNPs encapsulating Cd28 small interfering RNA (LPC‐LNP‐Cd28) knock down cancer cell CD28 without affecting T cells, inflame the tumor microenvironment, and overcome anti‐PD‐1 resistance.
Yangyang Chai, Keyu Wang, Jiali Fang, Shaorui Jia, Yansong Shi, Wanfeng Gao, Xinpeng Liu, Jiaqiang Li, Zenghui Cui, Yazhi Qian, Xiaosu Chen, Dan Ding, Xuetao Cao   +12 more
wiley   +1 more source

A quantile cure model with partially functional covariate effects. [PDF]

Stat Methods Med Res
Chen CM, Peng Y.
europepmc   +1 more source

Targeting DNGR‐1 with Fangchinoline Elevates Dendritic Cell Antigen Cross‐Presentation‐Mediated Antitumor Immunity in Melanoma

Advanced Science, EarlyView.
Fangchinoline is identified as a small‐molecule DNGR‐1 modulator that enhances dendritic‐cell cross‐presentation of tumor antigens. By engaging DNGR‐1 and activating Syk–Nox2 signaling, it promotes phagosomal ROS, antigen escape, MHC‐I presentation, and CD8+ T‐cell priming, thereby strengthening antitumor immunity and sensitizing tumors to PD‐1 ...
Yuan Liao, Zhenyang Ren, Jing Zhou, He Luo, Yuling Li, Dan Chen, Yuxiao Jiang, Canzhe Li, Mengyi Zheng, Anqi Li, Yao Wang, Yang Zhang, Dingye Wang, Yanjun Jiang, Jiangyong Gu, Biaoyan Du, Yafei Shi, Fang Liu, Jianyong Xiao, Kun Wang   +19 more
wiley   +1 more source